Cover Image

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting

Aim: To compare all-cause and acute lymphoblastic leukemia (ALL)-related healthcare resource utilization (HCRU) and costs among patients receiving inotuzumab ozogamicin (InO) and blinatumomab (Blina) for ALL in the first relapsed/refractory (R/R) setting. Patients & methods: We studied retrospec...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander Russell-Smith (Author), Louise Murphy (Author), Amy Nguyen (Author), Cori Blauer-Peterson (Author), Marilou Terpenning (Author), Feng Cao (Author), Shiqiang Li (Author), Tim Bancroft (Author), Noah Webb (Author), Stephanie Dorman (Author), Richa Shah (Author)
Format: Book
Published: Becaris Publishing Limited, 2023-12-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items